CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
3.49
1.76%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 16:30

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
Trading сonditions
Spread 0.03
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.020029 %
Charges from full value of position ($-3.81)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.020029%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.002193 %
Charges from full value of position ($-0.42)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.002193%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5.00%
Stock exchange France
Commission on trade 0%

Key Stats
Prev. Close 3.41
Open 3.41
1-Year Change -5.8%
Day's Range 3.38 - 3.52
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 3.41 -0.06 -1.73% 3.47 3.55 3.38
Dec 16, 2024 3.57 0.11 3.18% 3.46 3.57 3.44
Dec 13, 2024 3.49 -0.01 -0.29% 3.50 3.60 3.49
Dec 12, 2024 3.56 0.02 0.56% 3.54 3.57 3.49
Dec 11, 2024 3.55 -0.06 -1.66% 3.61 3.66 3.48
Dec 10, 2024 3.62 -0.05 -1.36% 3.67 3.72 3.62
Dec 9, 2024 3.72 0.14 3.91% 3.58 3.72 3.58
Dec 6, 2024 3.68 0.13 3.66% 3.55 3.69 3.54
Dec 5, 2024 3.65 -0.07 -1.88% 3.72 3.74 3.58
Dec 4, 2024 3.74 0.03 0.81% 3.71 3.80 3.61
Dec 3, 2024 3.73 -0.08 -2.10% 3.81 3.83 3.71
Dec 2, 2024 3.79 0.01 0.26% 3.78 3.87 3.66
Nov 29, 2024 3.84 0.03 0.79% 3.81 3.94 3.81
Nov 28, 2024 3.87 0.02 0.52% 3.85 3.95 3.85
Nov 27, 2024 3.90 -0.02 -0.51% 3.92 3.99 3.88
Nov 26, 2024 3.97 -0.04 -1.00% 4.01 4.11 3.87
Nov 25, 2024 4.02 -0.04 -0.99% 4.06 4.11 3.99
Nov 22, 2024 4.00 0.01 0.25% 3.99 4.09 3.86
Nov 21, 2024 4.00 -0.02 -0.50% 4.02 4.05 3.97
Nov 20, 2024 4.02 -0.13 -3.13% 4.15 4.20 3.99

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Genfit Company profile

About Genfit SA

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Financial summary

BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).

Equity composition

01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).

Industry: Biotechnology & Medical Research (NEC)

Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR

People also watch

ETH/USD

3,849.21 Price
-1.780% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.50 Price
-2.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01249

Gold

2,639.72 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0055%
Short position overnight fee -0.0027%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,921.20 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading